Back to Directory

CaTiffaney Griswould

Email

CGriswould@fhi360.org

Phone

202-884-8908

Institution

FHI 360

Address

FHI 360
359 Blackwell Street
Suite 200
Durham, NC 27701
USA

Request an Update

Affiliated Studies

IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States

DAIDS Number

Research Area

Study Status

IMPAACT 2048/HVTN 145: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants.

DAIDS Number

Research Area

Study Status

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV-1

DAIDS Number

Research Area

Study Status

IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

Research Area

Study Status

Show All